Bristol's Opdivo Diversifies Options In Liver Cancer

Response rate data supports yet another supplemental approval for Opdivo in an underserved tumor type that is becoming more competitive.

FDA approved background, 3D rendering, blue street sign

The US FDA's accelerated approval of Bristol-Myers Squibb Co.'s PD-1 inhibitor Opdivo for second-line hepatocellular carcinoma paves a path for checkpoint immunotherapies in yet another traditionally underserved tumor type.

FDA announced the new approval of Opdivo Sept. 22 for use after Bayer AG's oral, kinase inhibitor mainstay Nexavar...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip